

LYMPHOMA/CLL TRIALS OPEN TO RECRUITMENT AT THE RLUH

| Disease | Front Line or Relapsed/Refractory | Key entry criteria | Trial name & Treatment |
|-------------|-----------------------------------|---|--|
| DLBCL | Front line | | |
| | Relapsed/Refractory | At least 1 prior chemoimmunotherapy regimen, ineligible for ASCT, or progression following treatment with high dose chemo and ASCT | Harmony = Obinutuzumab in combination with Polatuzumab (anti CD79b) vedotin and Lenalidomide Phase 1b/2 |
| Follicular | Front line | High tumour burden | PETREA = PET scan post induction with R-chemo – PET positive = R or R2; PET negative = R or obs. |
| | Relapsed/Refractory | 2 prior treatments, no PI3K inhibitors, no progression on BTK inhibitors (FL) of Grade 1, 2, or 3a; prior treatment with one or more lines of standard therapy prior allogeneic hematologic stem cell transplant is excluded | ME-401 = double-blind, placebo-controlled, two-arm, phase 2 trial UTX-TGR-205 Arm A: Ublituximab + TGR-1202 Arm B: TGR-1202 |
| Mantle cell | Front line | Newly diagnosed, pre-treatment Unsuitable for PBSCT | MCL Biobank = blood and saliva samples at diagnosis ENRICH = IR, followed by daily I with R maintenance for 2 years v 6-8 cycles RB or R-CHOP, followed by R maintenance for 2 years. |
| | Relapsed/Refractory | Prior treatment with one or more lines of standard therapy Prior allogeneic hematologic stem cell transplant is excluded | UTX-TGR-205 Arm A: Ublituximab + TGR-1202 Arm B: TGR-1202 |

LYMPHOMA/CLL TRIALS OPEN TO RECRUITMENT AT THE RLUH

| Disease | Front Line or Relapsed/Refractory | Key entry criteria | Trial name & Treatment |
|--|-----------------------------------|---|--|
| Marginal zone | Relapsed/Refractory | prior treatment with one or more lines of standard therapy Prior allogeneic hematologic stem cell transplant is excluded | UTX-TGR-205 Arm A: Ublituximab + TGR-1202 Arm B: TGR-1202 |
| T-NHL (PTCL,ALCL,AI TL,ITL) | Front Line | PTCL Biobank | Blood & saliva samples at baseline, then 3 monthly at routine appointments, alongside data collection. |
| | | Observational study TYA | Non-Hodgkin Lymphoma in Young Adults 15-30 |
| | | AIL/ALCL/PTCL patients only. At least 1 prior line, measurable disease, PS 0-1. Prior allo-SCT excluded, as are those who've had prior PD1/PD-L1. | AUTO4-TL1 – CAR T cell treatment targeting TRBC1 for R/R TRBC1 positive selected T cell NHL. Refer patients to UCL. Ask JT for referral details. |
| SKIN LYMPHOMA | Front line | Newly diagnosed Mycosis fungoides or Sezary syndrome | PROCLIFI = diagnosis, annual and disease progression time points data collection only (may include tissue at a later date) |
| PTLD | Front line | CD20+, measurable disease, insufficient response to reduction in immunosuppression or not suitable for upfront reduction of immunosuppression | TIDAL = 7 weeks of IR, followed by continuing IR for low risk patients, or IR-CHOP for high risk patients. |
| CLL | Front line | Requiring treatment, fit for FCR, less than 20% P53 deletion, under 75. | FLAIR= FCR v IR v IV v I |